Related Experiment Videos
Immunosuppressive drugs and pregnancy
1Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, USA.
Obstetrics and Gynecology Clinics of North America
|September 1, 1997
Summary
This review summarizes immunosuppressive drug use in pregnancy for conditions like rheumatic diseases and organ transplants. It focuses on maternal and fetal effects, aiding clinical decision-making.
Area of Science:
- Immunology
- Pharmacology
- Obstetrics
Background:
- Immunosuppressive therapy is integral to managing various autoimmune and post-transplant conditions.
- Pregnancy presents unique challenges for managing patients requiring immunosuppression.
- Existing literature on immunosuppressive drug safety in pregnancy requires synthesis.
Purpose of the Study:
- To consolidate current knowledge on immunosuppressive drug use during pregnancy.
- To evaluate the impact of these therapies on maternal and fetal outcomes.
- To provide a resource for clinicians managing pregnant patients on immunosuppressants.
Main Methods:
- Systematic review of existing literature.
- Analysis of clinical studies and case reports.
- Focus on drug efficacy and safety profiles in pregnant populations.
Main Results:
- Data on specific immunosuppressive agents and their pregnancy outcomes are variable.
- Certain immunosuppressants demonstrate acceptable safety profiles under specific conditions.
- Risks and benefits must be individualized based on maternal disease severity and drug class.
Conclusions:
- Careful consideration and monitoring are essential when using immunosuppressive drugs in pregnancy.
- Further research is needed to optimize management strategies and long-term outcomes.
- Informed patient counseling is crucial for shared decision-making regarding immunosuppressive therapy during gestation.